We studied the effects of human T-lymphotropic virus type I (HTLV-I) on human endothelial cells in vitro. During cocultivation with an HTLV-I producer cell line (C91/PL), endothelial cells formed characteristic multinucleated syncytial giant cells. Inoculation with concentrated cellfree supernatant fluid from C91/PL cultures produced similar cytopathic effects, which were neutralized by pretreatment with HTLV-I specific human serum. HTLV-I antigens were detected in the cytoplasm of the multinucleated cells by indirect immunofluorescence. When endothelial cells showed maximal cytopathic changes, reverse transcriptase activity was demonstrated in the supernatant fluid and HTLV-I was isolated by cocultivation with peripheral blood mononuclear cells. This study demonstrates that HTLV-I tropism is not limited to lymphoid cells but extends to human endothelial cells as well.
This neoplasm occurs in clusters in southwestern Japan (3) , the Caribbean (4), central Africa (5) , and southeastern United States (6) . In vitro, HTLV-I is tropic for human lymphocytes, especially those with the T4 (helper-inducer) surface phenotype (7) , although infection of human osteogenic sarcoma cells (8) , lung cells (FL), and cervical carcinoma cells (HeLa) (9) has also been reported.
Endothelial cells are the putative target cells for Kaposi sarcoma (10, 11) , a tumor commonly seen in the acquired immunodeficiency syndrome (AIDS) (12) . We have been studying the pathogenesis of Kaposi sarcoma by evaluating in vitro susceptibility of endothelial cells to viruses implicated in the cause of AIDS. Recently, we have demonstrated that endothelial cells can be productively infected by cytomegalovirus (13) . Retroviruses have also been implicated in the pathogenesis of AIDS. Although the lymphadenopathyassociated virus (LAV) and the closely related or identical HTLV-III have received the greatest attention (14-18), HTLV-I has also been isolated from patients with AIDS (19) . We now report our findings of infection of human umbilical vein endothelial cells by HTLV-I.
MATERIALS AND METHODS
Cells and Virus. Early passage endothelial cells were obtained from R. Weinstein (Beth Israel Hospital, Boston). These cells were harvested from a human umbilical vein (20) and grown on a human fibronectin matrix while maintained on medium 199 supplemented with fetal calf serum (10%), endothelial cell growth factor (100 pig/ml), Hepes buffer (10 mM), L-glutamine (2 mM), penicillin (250 units/ml), and streptomycin (250 ,ug/ml) (21) . All cells expressed factor VIII-related antigen as demonstrated by direct immunofluorescence using fluoresceinated anti-human factor VIII antibody (Atlantic Antibody, Scarborough, ME). C91/PL, an HTLV-I producer T-cell line, was provided by R. Gallo (National Cancer Institute, Bethesda, MD) and maintained on RPMI medium 1640 containing fetal calf serum (20%), Hepes buffer, L-glutamine, and antibiotics.
Inoculation of Endothelial Cells with Cell-Associated HTLV-I. Endothelial cells grown to a density of 1 x 106 cells in 25-cm2 flasks (370C, 5% CO in air) were cocultivated with 1 x 106, 5 x 105, and 2 x 10 C91/PL cells that had been pretreated with mitomycin C (100 ,tg/ml, 30 min). These cell concentrations corresponded to multiplicities of infection (mois) of 1.0, 0.5, and 0.2 C91/PL cell/endothelial cell, respectively. Similarly, a control culture of 1 x 106 endothelial cells was inoculated with 1 x 106 cells of CEM, also known as CCRF-CEM, a virus-negative T-lymphoblastoid cell line (22) . After two media changes (4-5 days), the nonadherent C91/PL or CEM cells were lost from the cultures. The endothelial cells were not pretreated with enhancing agents such as Polybrene or DEAE-dextran.
Inoculation of Endothelial Cells with Cell-Free HTLV-I. Cell-free HTLV-I pellets were obtained by ultracentrifugation (100,000 x g, 60 min, 4°C) of 100 ml of preclarified (10,000 x g, 15 min) supernatant fluid from C91/PL cultures. The virus pellets were resuspended in a total of 2.5 ml of medium 199 and filtered through a 0.45-,um Nalgene filter. Endothelial cells (1 x 106 per 25 cm2) were incubated with 1 ml of this concentrated suspension for 2 hr at 37°C before complete medium was added. A parallel culture was similarly inoculated, but the inoculum was pretreated for 60 min at 37°C with 1 ml of 1:10 dilution of heat-inactivated (56°C, 60 min) HTLV-I specific serum (3740), provided by M. Essex (Harvard School of Public Health, Boston). This serum, obtained from a Japanese person from an HTLV-I endemic area, had a titer exceeding 1:1000 by indirect immunofluorescence for HTLV-I membrane antigens (23) .
Indirect Immunofluorescence. Endothelial cells were trypsinized and resuspended in phosphate-buffered saline before attachment to glass slides. After acetone fixation, cells were covered for 30 min with a 1:100 dilution of serum 3740 or a 1:250 dilution of murine monoclonal antibody against HTLV-I protein p19, obtained from B. Haynes (Duke University School of Medicine, Durham, NC). After three washes, the appropriate undiluted goat anti-human IgG-fluorescein isothiocyanate conjugate (Electronucleonics, Bethesda, MD) or a 1:40 dilution of rabbit anti-mouse F(ab')2-fluorescein isothiocyanate conjugate (Cappel Laboratories, Cochranville, PA) was added for 30 min. After three additional washes, the slides were mounted and examined under a Zeiss ultraviolet microscope.
Abbreviations: AIDS, acquired immunodeficiency syndrome; CPE, cytopathic effects; HTLV-I and HTLV-III, human T-lymphotropic virus types I and III, respectively; LAV, lymphadenopathy-associated virus; moi, multiplicity of infection; PBMC, peripheral blood mononuclear cells.
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. (26) (27) (28) (29) . In particular, HTLV-I can induce some human neoplastic cells to form multinucleated cells by fusion (9, 30 Endothelial cells are the putative target cells for Kaposi sarcoma (10, 11) , a neoplasm commonly seen in AIDS. HTLV-I was previously implicated in the, pathogenesis of AIDS (19, 23, 34) , but recent studies suggest that a related human retrovirus, HTLV-III or LAV, is the probable etiologic agent (14) (15) (16) (17) (18) . Nevertheless, HTLV-I has been isolated from patients with AIDS and may play a role in some of the manifestations observed. In view of our current findings, it will be important to study the effects of HTLV-III and/or LAV on human endothelial cells as well.
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